Home » Stocks » IMRA

IMARA Inc. (IMRA)

Stock Price: $7.25 USD 0.14 (1.97%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 127.42M
Revenue (ttm) n/a
Net Income (ttm) -49.22M
Shares Out 17.58M
EPS (ttm) -3.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $7.25
Previous Close $7.11
Change ($) 0.14
Change (%) 1.97%
Day's Open 7.05
Day's Range 7.04 - 7.34
Day's Volume 59,824
52-Week Range 6.61 - 62.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering ...

5 days ago - GlobeNewsWire

Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families Company will award grants totalin...

1 month ago - GlobeNewsWire

Atlanta, Georgia--(Newsfile Corp. - March 22, 2021) - Holzer & Holzer, LLC is investigating whether IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) complied with federal securities laws. On March 5...

1 month ago - Newsfile Corp

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses

1 month ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised ...

1 month ago - Newsfile Corp

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA).   Such investors are advised to contact R...

1 month ago - PRNewsWire

NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA).  Such investors are advised to contact Rob...

1 month ago - PRNewsWire

Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia

2 months ago - GlobeNewsWire

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

2 months ago - GlobeNewsWire

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

2 months ago - GlobeNewsWire

Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical...

3 months ago - GlobeNewsWire

Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap f...

4 months ago - Benzinga

Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment

5 months ago - GlobeNewsWire

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

5 months ago - GlobeNewsWire

Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experience in the p...

5 months ago - GlobeNewsWire

IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Patient Dosing Underway in Phase 2b clinical trials of IMR-687  in sickle cell disease and beta-thalassemia

6 months ago - GlobeNewsWire

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

6 months ago - GlobeNewsWire

Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease Forte is the first clinical ...

6 months ago - GlobeNewsWire

Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare Conference Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare C...

8 months ago - GlobeNewsWire

BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

8 months ago - GlobeNewsWire

IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial

8 months ago - GlobeNewsWire

Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease Highly selective, potent, small molecule inhibitor...

8 months ago - GlobeNewsWire

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

9 months ago - GlobeNewsWire

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

9 months ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: COWN, GAN, GTY
10 months ago - Zacks Investment Research

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

10 months ago - GlobeNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, KROS, PCVX, RNA, RPTX, XBI ...
10 months ago - CNN Business

Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Company expands program...

10 months ago - GlobeNewsWire

BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients ...

10 months ago - GlobeNewsWire

Imara Inc. IMRA, +12.66% announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment.

10 months ago - Market Watch

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monothe...

10 months ago - GlobeNewsWire

About IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
IPO Date
Mar 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
IMRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 37.50, which is an increase of 417.24% from the latest price.

Price Target
$37.50
(417.24% upside)
Analyst Consensus: Strong Buy